United Therapeutics' Orenitram delays disease progression in Phase III for PAH

By Elizabeth S. Eaton | Aug 17, 2018 | 3:14 AM GMT

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III